Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cannabinoids and neuroinflammation.

Literature DB >> 14757702

Cannabinoids and neuroinflammation.

Abstract

Growing evidence suggests that a major physiological function of the cannabinoid signaling system is to modulate neuroinflammation. This review discusses the anti-inflammatory properties of cannabinoid compounds at molecular, cellular and whole animal levels, first by examining the evidence for anti-inflammatory effects of cannabinoids obtained using in vivo animal models of clinical neuroinflammatory conditions, specifically rodent models of multiple sclerosis, and second by describing the endogenous cannabinoid (endocannabinoid) system components in immune cells. Our aim is to identify immune functions modulated by cannabinoids that could account for their anti-inflammatory effects in these animal models.

Entities: Chemical Disease

Mesh：

Substances：
Cannabinoids

Year: 2004 PMID： 14757702 PMCID： PMC1574256 DOI： 10.1038/sj.bjp.0705667

Source DB: PubMed Journal: Br J Pharmacol ISSN： 0007-1188 Impact factor: 8.739

170 in total

1. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity.

Authors: M E Abood; G Rizvi; N Sallapudi; S D McAllister
Journal: Neurosci Lett Date: 2001-08-31 Impact factor: 3.046

Review 2. Inflammation in multiple sclerosis: the good, the bad, and the complex.

Authors: Gianvito Martino; Luciano Adorini; Peter Rieckmann; Jan Hillert; Boris Kallmann; Giancarlo Comi; Massimo Filippi
Journal: Lancet Neurol Date: 2002-12 Impact factor: 44.182

3. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes.

Authors: M Maccarrone; L De Petrocellis; M Bari; F Fezza; S Salvati; V Di Marzo; A Finazzi-Agrò
Journal: Arch Biochem Biophys Date: 2001-09-15 Impact factor: 4.013

Review 4. An experimental model system for HIV-1-induced brain injury.

Authors: H E Gendelman; P Genis; M Jett; Q H Zhai; H S Nottet
Journal: Adv Neuroimmunol Date: 1994

5. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia.

Authors: Francisco Molina-Holgado; Emmanuel Pinteaux; Jonathan D Moore; Eduardo Molina-Holgado; Carmen Guaza; Rosemary M Gibson; Nancy J Rothwell
Journal: J Neurosci Date: 2003-07-23 Impact factor: 6.167

6. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.

Authors: Andis Klegeris; Christopher J Bissonnette; Patrick L McGeer
Journal: Br J Pharmacol Date: 2003-06 Impact factor: 8.739

7. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.

Authors: Ji Zhang; Cyrla Hoffert; Huy Khang Vu; Thierry Groblewski; Sultan Ahmad; Dajan O'Donnell
Journal: Eur J Neurosci Date: 2003-06 Impact factor: 3.386

8. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells.

Authors: M Bouaboula; B Bourrié; M Rinaldi-Carmona; D Shire; G Le Fur; P Casellas
Journal: J Biol Chem Date: 1995-06-09 Impact factor: 5.157

9. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide.

Authors: M Wartmann; D Campbell; A Subramanian; S H Burstein; R J Davis
Journal: FEBS Lett Date: 1995-02-13 Impact factor: 4.124

Review 10. Neuropathology of multiple sclerosis-new concepts.

Authors: Barbara Kornek; Hans Lassmann
Journal: Brain Res Bull Date: 2003-08-15 Impact factor: 4.077

97 in total

1. Exposure of Adolescent Mice to Delta-9-Tetrahydrocannabinol Induces Long-Lasting Modulation of Pro- and Anti-Inflammatory Cytokines in Hypothalamus and Hippocampus Similar to that Observed for Peripheral Macrophages.

Authors: Sarah Moretti; Silvia Franchi; Mara Castelli; Giada Amodeo; Lorenzo Somaini; Alberto Panerai; Paola Sacerdote
Journal: J Neuroimmune Pharmacol Date: 2015-02-10 Impact factor: 4.147

Review 2. Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors: Simone Tambaro; Marco Bortolato
Journal: Recent Pat CNS Drug Discov Date: 2012-04-01

Review 3. Cannabinoid receptors and endocannabinoids: evidence for new players.

Authors: Ken Mackie; Nephi Stella
Journal: AAPS J Date: 2006-04-28 Impact factor: 4.009

4. Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

Authors: I J Lever; T M Pheby; A S C Rice
Journal: Br J Pharmacol Date: 2007-03-20 Impact factor: 8.739

9. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.

Authors: Maheswari Rajasekaran; Lisa K Brents; Lirit N Franks; Jeffery H Moran; Paul L Prather
Journal: Toxicol Appl Pharmacol Date: 2013-03-26 Impact factor: 4.219

Review 10. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors: R G Pertwee
Journal: Br J Pharmacol Date: 2007-09-10 Impact factor: 8.739